Look back at pharma news in week to November 30

2 December 2018

By Barbara Obstoj-Cardwell. Editor

News last week on the clinical trial front included disappointing results with Vectura’s VR475 in asthma, causing the company to abandon further development of the drug. There was better news for Vertex, which presented positive data on its VX 659 in cystic fibrosis. Regulatory news included US Food and Drug Administration approval for Bayer and Loxo Oncology’s TRK inhibitor Vitrakvi in solid tumors. Elsewhere, Roche announced it is buying US biotech start-up Jecure Therapeutics, aiming to join the non-alcoholic steatohepatitis (NASH) race, and Moderna Therapeutics plans IPO valued at over $500 million, making it the largest ever development-stage biotech IPO.

Vectura’s VR475 runs out of puff

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK